S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
ETR:HNL

Dr. Hönle AG (HNL.F) Stock Forecast, Price & News

€56.30
+0.50 (+0.90 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
€55.10
Now: €56.30
€56.30
50-Day Range
€51.10
MA: €55.03
€57.40
52-Week Range
€24.45
Now: €56.30
€60.40
Volume4,040 shs
Average VolumeN/A
Market Capitalization$341.28 million
P/E Ratio39.10
Dividend Yield1.44%
BetaN/A
Dr. Hönle AG operates in the UV market worldwide. It operates through three segments: Equipment & Systems, Glass & Lamps, and Adhesives. The Equipment & Systems segment offers UV equipment and systems, LED-UV units, IR units, inert systems, disinfection systems, solar simulation systems and light fixtures, lighting systems, UV measuring technology products, UV-adhesives, and components and replacement parts. This segment also provides hot air systems, and powder spraying and extraction systems for sheet-fed offset printing; UV dryers for Web printing; UV systems with nitrogen inertisation; and drying systems. Its products are used for drying inks and coatings, curing adhesives and plastics, disinfecting surfaces, and sunlight simulation. The Glass & Lamps segment offers UV low and medium pressure lamps; infrared emitters; electronic power supplies; UV sensors and measuring technology products; UV measuring devices; and submersible and immersion tube systems, as well as accessories. This segment also provides UV bulbs; and quartz glass tubing and rods for the lamp, automotive, semiconductor, and fiber cable industries. The Adhesives segment offers industrial, UV, medical grade, and conductive adhesives; dosing systems; potting and sealing compounds; and UV curing units. Dr. Hönle AG was founded in 1976 and is headquartered in Gräfelfing, Germany.

MarketRank

Overall MarketRank

1.29 out of 5 stars

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Electronic Components
Sub-IndustryN/A
CUSIPN/A
CIKN/A
Phone49 89 85608 0
Employees580

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$98.29 million
Cash Flow€1.95 per share
Book Value€16.33 per share

Profitability

Miscellaneous

Market Cap$341.28 million
Next Earnings DateN/A
OptionableNot Optionable
€56.30
+0.50 (+0.90 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HNL News and Ratings via Email

Sign-up to receive the latest news and ratings for HNL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dr. Hönle AG (HNL.F) (ETR:HNL) Frequently Asked Questions

How has Dr. Hönle AG (HNL.F)'s stock been impacted by Coronavirus (COVID-19)?

Dr. Hönle AG (HNL.F)'s stock was trading at €34.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HNL shares have increased by 62.2% and is now trading at €55.80.
View which stocks have been most impacted by COVID-19
.

Is Dr. Hönle AG (HNL.F) a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dr. Hönle AG (HNL.F) in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Dr. Hönle AG (HNL.F) stock.
View analyst ratings for Dr. Hönle AG (HNL.F)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Dr. Hönle AG (HNL.F)?

Wall Street analysts have given Dr. Hönle AG (HNL.F) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dr. Hönle AG (HNL.F) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Is Dr. Hönle AG (HNL.F) a good dividend stock?

Dr. Hönle AG (HNL.F) pays an annual dividend of €0.80 per share and currently has a dividend yield of 1.44%. The dividend payout ratio of Dr. Hönle AG (HNL.F) is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%.
View Dr. Hönle AG (HNL.F)'s dividend history.

What price target have analysts set for HNL?

2 analysts have issued 1-year price targets for Dr. Hönle AG (HNL.F)'s stock. Their forecasts range from €65.00 to €68.50. On average, they anticipate Dr. Hönle AG (HNL.F)'s share price to reach €66.75 in the next year. This suggests a possible upside of 19.6% from the stock's current price.
View analysts' price targets for Dr. Hönle AG (HNL.F)
or view Wall Street analyst' top-rated stocks.

Who are some of Dr. Hönle AG (HNL.F)'s key competitors?

Who are Dr. Hönle AG (HNL.F)'s key executives?

Dr. Hönle AG (HNL.F)'s management team includes the following people:
  • Dr. Norbert Haimerl M.B.A., CFO. MD of IT, HR & Investor Relations and Member of Management Board (Age 59, Pay $898k)
  • Mr. Heiko Runge Grad. Eng., MD of Sales & Marketing and Member of Management Board (Age 57, Pay $866k)
  • Mr. Rainer Pumpe, MD of Devel. & Production and Member of the Management Board
  • Peter Weinert, Head of Investor Relations

What is Dr. Hönle AG (HNL.F)'s stock symbol?

Dr. Hönle AG (HNL.F) trades on the ETR under the ticker symbol "HNL."

What is Dr. Hönle AG (HNL.F)'s stock price today?

One share of HNL stock can currently be purchased for approximately €55.80.

How big of a company is Dr. Hönle AG (HNL.F)?

Dr. Hönle AG (HNL.F) has a market capitalization of $338.25 million and generates $98.29 million in revenue each year. Dr. Hönle AG (HNL.F) employs 580 workers across the globe.

What is Dr. Hönle AG (HNL.F)'s official website?

The official website for Dr. Hönle AG (HNL.F) is www.hoenle.de.

How can I contact Dr. Hönle AG (HNL.F)?

The company can be reached via phone at 49 89 85608 0.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.